H. Lundbeck A/S won U.S. FDA marketing clearance for the first intravenous medication approved for the preventative treatment of migraine.
Redwood City, California-based Karius closed on a $165 million Series B round.
The U.S. Food and Drug Administration is compiling a list of drugs that are at risk of shortage if the coronavirus outbreak in China continues to worsen.
The U.S. Food and Drug Administration approved Michigan-based Esperion’s oral, once-daily, non-statin LDL-cholesterol lowering medicine Nexletol (bempedoic acid).
Seqirus snagged U.S. FDA approval for Fluad Quadrivalent, the first quadrivalent adjuvanted influenza vaccine developed to help protect adults 65 years and older against seasonal influenza.
Sanofi plans to create a standalone company dedicated to making active pharmaceutical ingredients, components that are biologically active in a drug, and will decide whether to list the API business on Euronext Paris by 2022.
